Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system

• Hlavní autoři: Psota M (Autor), Psenkova MB (Autor), Racekova N (Autor), Ramirez de Arellano A (Autor), Vandebrouck T (Autor), Hunt B (Autor)
• Médium: Kniha
• Vydáno: Dove Medical Press, 2017-12-01T00:00:00Z.
• Témata: article
• On-line přístup: Connect to this object online.

Marek Psota,1 Maria Bucek Psenkova,1 Natalia Racekova,2 Antonio Ramirez de Arellano,3 Tom Vandebrouck,4 Barnaby Hunt5 1Pharm-In, Ltd., 2Novo Nordisk Ltd., Bratislava, Slovakia; 3Novo Nordisk Ltd., Madrid, Spain; 4Novo Nordisk nv, Brussels, Belgium; 5Ossian Health Economics and Communications, Basel,...